TSVT vs. IMMP, PYXS, HOWL, ALDX, DSGN, ME, FHTX, CTNM, VERU, and CDT
Should you be buying 2seventy bio stock or one of its competitors? The main competitors of 2seventy bio include Immutep (IMMP), Pyxis Oncology (PYXS), Werewolf Therapeutics (HOWL), Aldeyra Therapeutics (ALDX), Design Therapeutics (DSGN), 23andMe (ME), Foghorn Therapeutics (FHTX), Contineum Therapeutics (CTNM), Veru (VERU), and Conduit Pharmaceuticals (CDT). These companies are all part of the "pharmaceutical preparations" industry.
Immutep (NASDAQ:IMMP) and 2seventy bio (NASDAQ:TSVT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.
Immutep received 284 more outperform votes than 2seventy bio when rated by MarketBeat users. Likewise, 72.37% of users gave Immutep an outperform vote while only 60.98% of users gave 2seventy bio an outperform vote.
Immutep has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500. Comparatively, 2seventy bio has a beta of 1.87, indicating that its share price is 87% more volatile than the S&P 500.
Immutep has a net margin of 0.00% compared to Immutep's net margin of -313.51%. 2seventy bio's return on equity of 0.00% beat Immutep's return on equity.
In the previous week, 2seventy bio had 12 more articles in the media than Immutep. MarketBeat recorded 15 mentions for 2seventy bio and 3 mentions for Immutep. 2seventy bio's average media sentiment score of 0.65 beat Immutep's score of 0.04 indicating that Immutep is being referred to more favorably in the media.
2.3% of Immutep shares are held by institutional investors. Comparatively, 93.9% of 2seventy bio shares are held by institutional investors. 3.1% of Immutep shares are held by company insiders. Comparatively, 2.6% of 2seventy bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Immutep has higher earnings, but lower revenue than 2seventy bio.
Immutep currently has a consensus price target of $8.50, indicating a potential upside of 189.12%. 2seventy bio has a consensus price target of $12.86, indicating a potential upside of 167.30%. Given 2seventy bio's stronger consensus rating and higher probable upside, analysts clearly believe Immutep is more favorable than 2seventy bio.
Summary
Immutep beats 2seventy bio on 12 of the 17 factors compared between the two stocks.
Get 2seventy bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TSVT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TSVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
2seventy bio Competitors List
Related Companies and Tools
